SCHEMBL17875733

SCHEMBL17875733

c1ccc2c(c1)oc1ccc(-c3ccc4c(c3)CSCc3ccc(-c5ccc6oc7ccccc7c6c5)cc3-4)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
RAB9A P51151 1/20 0.40
AHR P35869 2/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
PLA2G2A P14555 4/20 0.35
PLA2G4A P47712 4/20 0.35
CASP3 P42574 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17875740 0.96 MEN1 (0.37) MAPTSMN1; SMN2NPC1KDM4EMEN1
SCHEMBL17875792 0.94 MAPT (0.44) MAPTSMN1; SMN2NPC1KDM4EMEN1
SCHEMBL17875744 0.94 PLA2G2A (0.40) MAPTSMN1; SMN2NPC1KDM4EMEN1
SCHEMBL17875766 0.94 PLA2G2A (0.40) MAPTSMN1; SMN2NPC1KDM4EMEN1
SCHEMBL17875727 0.92 AHR (0.40) MAPTSMN1; SMN2NPC1KDM4EMEN1
SCHEMBL17875741 0.92 ALOX5 (0.36) MAPTSMN1; SMN2NPC1KDM4EMEN1
SCHEMBL17875759 0.92 ALOX5 (0.36) MAPTSMN1; SMN2NPC1KDM4EMEN1
SCHEMBL17875739 0.91 ALOX5 (0.48) MAPTSMN1; SMN2NPC1KDM4EMEN1
SCHEMBL17875732 0.91 ALOX5 (0.48) MAPTSMN1; SMN2NPC1KDM4EMEN1
SCHEMBL17875788 0.90 MEN1 (0.41) MAPTSMN1; SMN2NPC1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-03-03 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same CRY1, CRY2, CCNE2 MAPT 2144/4885SMN1; SMN2 3237/4885NPC1 2673/4885
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNE2 MAPT 2144/4885SMN1; SMN2 3237/4885NPC1 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.